PharmaMar R&D Day NY April 2017

New York, April 24, 2017

Please join PharmaMar for a Research & Development Day in New York City on April 24th.

Management to discuss scientific pipeline including Phase 3 pivotal study with Lurbinectedin (PM1183) for platinum-resistant ovarian cancer.

Agenda:

  • History and Evolution of PharmaMar, by its founder José Maria Fernandez
  • Current and prospective clinical trials, by the Chief Medical Officer
  • Dr.Martin Forster, UCL, expert in small cell lung cancer
  • Dr. Melinda Telli, Stanford, expert in hereditary breast cancers
  • Discussion on Lurbinectedin mechanism of action compared to Yondelis
  • Discussion of potential synergy with IO and PARPs
  • Sue Friedman, Executive Director FORCE, patient advocacy women’s hereditary cancers
  • Strategy & Where PharmaMar will be 5 years with the head of Oncology, Luis Mora

Expert Guest Speakers to Include:

Melina Telli, MD
Stanford University
Stanford School of Medicine, Stanford, CA

Dr Martin Forster, MBBS MRCP PhD
UCL Cancer Institute
University College Hospital, London, UK

Sue Friedman, DVM
Executive Director
Facing Our Risks of Cancer Empowered (FORCE)

For more information or to RSVP please contact Patrick Till (ptill@troutgroup.com)

Register / Log Back in

Additional menu options can be found in the menu bar on the left or at the top.